Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin

Simple item page
dc.contributor.authorPhillips, Patricia G.
dc.contributor.authorCui, Huadong
dc.contributor.authorAbdel, Hani Nabi
dc.contributor.authorSajjad, Munawwar
dc.contributor.authorBernacki, Ralph
dc.contributor.authorVeith, Jean
dc.contributor.authorMousa, Shaker A.
dc.contributor.buuauthorYalçın, Murat
dc.contributor.departmentUludağ Üniversitesi/Veterinerlik Fakültesi/Fizyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-5600-8162tr_TR
dc.contributor.researcheridAAG-6956-2021tr_TR
dc.contributor.scopusid57192959734tr_TR
dc.date.accessioned2021-12-14T08:28:54Z
dc.date.available2021-12-14T08:28:54Z
dc.date.issued2011-02
dc.description.abstractBackground: Recent prospective clinical trials of low molecular weight heparins (LMWHs) have demonstrated that these agents may provide significant advantages in terms of progression-free and overall survival in certain subgroups of cancer patients. The mechanisms of improved survival associated with LMWHs are not known, and may involve direct and/or indirect effects on tumor growth. The purpose of this study was to investigate the effects of LMWH and a sulfated non-anticoagulant LMWH (S-NACH) on tumor chemotherapeutic uptake and chemoresponse. Materials and Methods: LMWH and S-NACH were tested for their ability to reduce tumor growth and tumor-associated angiogenesis using three different in vivo models. Biodistribution studies were undertaken to determine the effect of these agents on uptake of paclitaxel (PACL) and doxorubicin (Dox) by breast cancer tumor xenografts. Results: LMWH and S-NACH (10 mg/kg s.c. daily) effectively limited tumor growth of human A549 lung adenocarcinoma xenografts in the nude mouse. In an MDA453/LCC6 breast tumor xenograft model, PACL plus S-NACH showed significant (p<0.01) tumor growth suppression and improved survival when compared to PACL alone. LMWH increased [I124-]-PACL uptake into MDA453/LCC6 tumors, with tumor:muscle ratios several fold greater than that of [I124-]-PACL alone 24 h post-injection. Similarly, LMWH and S-NACH significantly (p<0.01) increased the uptake of Dox by 1.5-2 fold in MCF7 Dox-resistant tumor xenografts. Conclusion: Protocols utilizing adjuvant or neoadjuvant therapy with LMWH or S-NACH could lead to increased tumor chemo responsiveness, potentially overcoming tumor chemoresistance.en_US
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA (CA121636)en_US
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) (R43CA121636)en_US
dc.identifier.citationPhillips, P. G. vd. (2011). "Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin". Anticancer Research, 31(2), 411-419.en_US
dc.identifier.endpage419tr_TR
dc.identifier.issn0250-7005
dc.identifier.issn1791-7530
dc.identifier.issue2tr_TR
dc.identifier.pubmed21378319tr_TR
dc.identifier.scopus2-s2.0-79953246591tr_TR
dc.identifier.startpage411tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/23238
dc.identifier.volume31tr_TR
dc.identifier.wos000288684800005tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherInt Inst Anticancer Researchen_US
dc.relation.collaborationSanayitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalAnticancer Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectNon-anticoagulant heparinsen_US
dc.subjectChemotherapyen_US
dc.subjectHeparinsen_US
dc.subjectTissue factoren_US
dc.subjectCanceren_US
dc.subjectSurvivalen_US
dc.subjectInhibitionen_US
dc.subjectTherapyen_US
dc.subjectAngiogenesisen_US
dc.subjectMetastasisen_US
dc.subjectTinzaparinen_US
dc.subjectMechanismsen_US
dc.subjectResistanceen_US
dc.subject.emtreeDoxorubicinen_US
dc.subject.emtreeLow molecular weight heparinen_US
dc.subject.emtreePaclitaxelen_US
dc.subject.emtreeSulfated non anticoagulant low molecular weight heparinen_US
dc.subject.emtreeTinzaparinen_US
dc.subject.emtreeAnimal experimenten_US
dc.subject.emtreeAnimal modelen_US
dc.subject.emtreeAnimal tissueen_US
dc.subject.emtreeAntiangiogenic activityen_US
dc.subject.emtreeAntineoplastic activityen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBreast canceren_US
dc.subject.emtreeCancer inhibitionen_US
dc.subject.emtreeCancer resistanceen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug distributionen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug potentiationen_US
dc.subject.emtreeDrug uptakeen_US
dc.subject.emtreeEmbryoen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeIn vivo studyen_US
dc.subject.emtreeLung adenocarcinomaen_US
dc.subject.emtreeMouseen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeTumor xenograften_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.meshAdenocarcinomaen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibiotics, antineoplasticen_US
dc.subject.meshAnticoagulantsen_US
dc.subject.meshAntineoplastic agents, phytogenicen_US
dc.subject.meshBreast neoplasmsen_US
dc.subject.meshCell line, tumoren_US
dc.subject.meshChick embryoen_US
dc.subject.meshDoxorubicinen_US
dc.subject.meshDrug interactionsen_US
dc.subject.meshDrug resistance, neoplasmen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeparin, low-molecular-weighten_US
dc.subject.meshHumansen_US
dc.subject.meshLodine radioisotopesen_US
dc.subject.meshLung neoplasmsen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, nudeen_US
dc.subject.meshPaclitaxelen_US
dc.subject.meshTissue distributionen_US
dc.subject.meshXenograft model antitumor assaysen_US
dc.subject.scopusVenous Thromboembolism; Low Molecular Weight Heparin; Anticoagulant Agenten_US
dc.subject.wosOncologyen_US
dc.titleIncreased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparinen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus